Latest news
EyeWorld Weekly, August 7, 2026 - EyeWorldEyeWorld · Fri, 07 Aug 2026 16:04:01 GMTTarsus pays $450M for Alkeus and its ph. 3 retinal disease drug - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 14:30:00 GMTTarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition - ReutersReuters · Thu, 06 Aug 2026 13:55:38 GMTEvidence on Gene Therapy for Pediatric IRDs Remains Uneven - Review of OptometryReview of Optometry · Wed, 05 Aug 2026 17:39:26 GMTOpus Genetics Completes Enrollment in Phase 3 Trial of Gene Therapy for Inherited Retinal Disease - Eyewire+Eyewire+ · Tue, 04 Aug 2026 13:06:40 GMTWhy inherited retinal disease treatment requires more than gene therapy - Drug Target ReviewDrug Target Review · Tue, 04 Aug 2026 08:55:59 GMTOpus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 07:38:27 GMTOpus Genetics Completes Enrollment in Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 11:15:00 GMT